Outcome of Adolescents with Acute Lymphoblastic Leukemia Treated by Pediatrics versus Adults Protocols

Table 2

Pediatric adopted BFM90 high risk.

Prephase
Prednisolone	60 mg/m^2	PO	(D1–7)
Induction
Prednisolone	60 mg/m^2	PO	(D1–28)
Vincristine	1.5 mg/m^2	IV	(D8, 15, 22, 29)
Epirubicin	30 mg/m^2	IV	(D8, 15, 22, 29)
L-asparaginase	10.000 u/m^2	IM	(D19, 22, 25, 28, 31, 34, 37, 40)
Triple age adjusted IT		IT	(D8, 15, 22, 29)
High risk I (HRI)
Dexamethasone	20 mg/m^2	PO	(D1–5)
Vincristine	1.5 mg/m^2	IV	(D1–5)
6-Mercaptopurine	25 mg/m^2	PO	(D1–5)
MTX (6 HR infusion)	3 g/m^2	IV	(D1)
L-asparaginase	25.000 u/m^2	IM	(D6)
Triple age adjusted IT		IT	(D1)
High risk II (HRII)
Dexamethasone	20 mg/m^2	PO	(D1–5)
Vincristine	1.5 mg/m^2	IV	(D1)
Ifosfamide	400 mg/m^2	IV	(D1–5)
MTX (6 HR infusion)	3 g/m^2	IV	(D1)
Epirubicin	50 mg/m^2	IV	(D5)
L-asparaginase	25.000 u/m^2	IM	(D6)
Triple age adjusted IT		IT	(D1)
High risk III (HRIII)
Dexamethasone	20 mg/m^2	PO	(D1–5)
Vincristine	5 mg/m^2	IV	(D1)
Cytarabine	1 g/m^2/12 h	IV	(D2–5)
Etoposide	150 mg/m^2	IV	(D2–5)
L-asparaginase	25.000 u/m^2	IM	(D6)
Triple age adjusted IT		IT	(D1)
Total number of HR are 9 cycles; then if the patient is in CR after the 9th, cranial prophylaxis (18 g) will be given
	Maintenance maximum two years with pulses of
Vincristine	1.5 mg/m^2	IV	(D1)
Prednisolone	40 mg/m^2	PO	For 7 days every two months
6-Mercaptopurine	25 mg/m^2	PO	Daily
MTX	20 mg/m^2	IM	Weekly
Triple intrathecal (Methotrexate, Ara-C, hydrocortisone)		IT	Every 2 months till the end of maintenance

D: Day, HR: high risk, Gy: gray, MTX: Methotrexate, PO: per oral.